Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial comparing ofatumumab with rituximab for diffuse large B cell or follicular lymphoma (ORCHARRD)
Cancer type:
Status:
Phase:
- come back
- continued to grow after treatment
More about this trial
- find out how well DHAP and ofatumumab worked compared to DHAP and rituximab
- learn more about the side effects
Summary of results
The trial team found that DHAP and ofatumumab worked no better than DHAP and rituximab for people with DLBCL or follicular lymphoma that had come back. Or whose treatment had stopped working.
The researchers published the results in February 2017. The trial took place worldwide.
Treatment
447 people took part. They were put into treatment groups at random and:
- 225 had DHAP and rituximab
- 222 had DHAP and ofatumumab
- how well the treatment worked
- how many people were living before their cancer started to grow again
- how long people lived after treatment
- an increased risk of infection
- bleeding and bruising
- an increased risk of infection with a fever (febrile neutropenia)
- kidney problems
- bleeding and bruising
- being sick
- skin rash
- changes to blood tests that show how the kidneys are working
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Gustaaf W. van Imhoff
Dr Andrew McMillian (UK)
Supported by
Experimental Cancer Medicine Centre (ECMC)
GlaxoSmithKline (GSK)
HOVON Dutch-Belgian Cooperative Trial Group for Hematology-Oncology
National Institute for Health Research Cancer Research Network (NCRN)
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040